Edwards Lifesciences Corporation (NYSE:EW) Stock Has Average Price Target of $100.27

Shares of Edwards Lifesciences Corporation (NYSE:EW) have been assigned a consensus recommendation of “Moderate Buy” from the twenty-three brokerages that are currently covering the company, MarketBeat.com reports. Six equities research analysts have rated the stock with a hold recommendation and seventeen have issued a buy recommendation on the company. The average 12-month target price among brokers that have covered the stock in the last year is $100.27.

A number of research analysts have recently commented on the company. Royal Bank Of Canada raised their target price on Edwards Lifesciences from $100.00 to $110.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Leerink Partners raised Edwards Lifesciences from a “market perform” rating to an “outperform” rating and upped their price target for the stock from $87.00 to $101.00 in a research note on Friday, July 24th. Wall Street Zen downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Saturday. Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Friday, July 17th. Finally, Truist Financial boosted their target price on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a report on Thursday, July 16th.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $86.97 on Friday. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The firm’s fifty day simple moving average is $88.47 and its 200 day simple moving average is $86.02. The stock has a market cap of $50.08 billion, a P/E ratio of 49.99, a price-to-earnings-growth ratio of 2.26 and a beta of 0.85. Edwards Lifesciences has a twelve month low of $72.30 and a twelve month high of $96.29.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The company had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.70 billion. During the same period in the prior year, the firm earned $0.67 earnings per share. Edwards Lifesciences’s revenue was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, research analysts predict that Edwards Lifesciences will post 3 EPS for the current year.

Insider Activity

In other news, VP Daniel J. Lippis sold 619 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total transaction of $56,966.57. Following the completion of the transaction, the vice president directly owned 40,034 shares of the company’s stock, valued at $3,684,329.02. The trade was a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Annette Brüls sold 2,644 shares of the business’s stock in a transaction on Friday, August 28th. The shares were sold at an average price of $89.98, for a total transaction of $237,907.12. Following the sale, the vice president owned 17,984 shares of the company’s stock, valued at approximately $1,618,200.32. This represents a 12.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 5,045 shares of company stock worth $455,341 over the last three months. 0.31% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Pin Oak Investment Advisors Inc. purchased a new position in shares of Edwards Lifesciences during the 2nd quarter worth $26,000. TrinityBridge Ltd bought a new stake in Edwards Lifesciences during the second quarter valued at about $27,000. MV Capital Management Inc. purchased a new stake in Edwards Lifesciences in the fourth quarter worth about $26,000. Hanson & Doremus Investment Management purchased a new stake in Edwards Lifesciences in the first quarter worth about $25,000. Finally, Hilton Head Capital Partners LLC bought a new position in shares of Edwards Lifesciences in the fourth quarter worth about $28,000. Institutional investors own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation is a medical technology company focused on therapies for structural heart disease and other cardiovascular conditions. The company develops and manufactures heart valve replacement and repair technologies, including transcatheter aortic valve replacement systems, surgical heart valves, transcatheter mitral and tricuspid therapies, and related delivery systems and accessories.

Founded in 1958 by engineer Miles “Lowell” Edwards, the company helped pioneer artificial heart valves and has played a significant role in the development of transcatheter valve replacement.